Systemic Lupus Erythematosus News and Research

RSS

Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.

Steroids used to treat inflammatory disease increases risk of cardiovascular disease

Researchers have found that prescribed low doses of steroids, often to combat inflammatory diseases, are at an increased risk of cardiovascular diseases.

3 Dec 2020

Mymee's clinical trial demonstrates health-related quality of life improvements in lupus patients

Mymee Inc., the leading digital health company that empowers those who suffer from autoimmune disease to reclaim their health, today announced the publication of it’s study assessing the Mymee Program as adjunct care in patients with Systemic Lupus Erythematosus in the Journal of Medical Internet Research .

9 Nov 2020

Study: Hydroxychloroquine has no effect on abnormal heart rhythm in lupus patients with CKD

New research shows that adults with lupus who take the antimalarial drug, hydroxychloroquine, do not have any differences in their corrected QT (QTc) intervals, an electrocardiogram (EKG) measurement of the heart's electrical signals, even if they have chronic kidney disease (CKD), a complication of lupus that can be associated with increased levels of the medication.

9 Nov 2020

Black patients with lupus have higher risk of stroke and ischemic heart disease

New research reveals that, in the U.S., Black patients with lupus have a threefold higher risk of stroke and a 24-fold higher risk of ischemic heart disease.

6 Nov 2020

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX), a prophylactic therapy to help prevent pneumocystis pneumonia, are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies.

6 Nov 2020

Patients with rheumatic diseases reported antimalarial drug shortages during COVID-19

A new study shows that patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of antimalarial drugs, including hydroxychloroquine, during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible COVID-19 treatment.

6 Nov 2020

Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA or lupus patients

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, discovers that use of hydroxychloroquine, a generic drug, does not cause any significant differences in QTc length or prolonged QTc, key measures of heart rate, in people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

6 Nov 2020

Pre-existing anti-IFN autoantibodies may worsen COVID-19 in lupus patients

“Our observations suggest that the presence of these autoantibodies may predispose SLE patients to infection with SARS-CoV-2 with a more severe presentation and represent an additional risk factor in this patient population,” write Sarthak Gupta and colleagues from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

5 Nov 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

Exuberant activation of immune cells in severe COVID-19 resembles lupus

In severe cases of COVID-19, Emory researchers have been observing an exuberant activation of immune cells, resembling acute flares of systemic lupus erythematosus (SLE), an autoimmune disease.

9 Oct 2020

Auto-antibodies may explain why some people develop severe COVID-19

Now, a new study by an international team of health experts shows that some life-threatening cases of COVID-19 can be traced to specific weak spots in the patients' immune system.

28 Sep 2020

Targeted treatment for systemic lupus erythematosus

A team of researchers from Charité - Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus.

22 Sep 2020

Memory B cells indicate durable immunity in COVID-19

Now a new study by researchers at SUNY Upstate Medical University and published recently on the preprint server medRxiv in September 2020 shows that memory B cells are upregulated in convalescent COVID-19 patients, correlating with a better immune response and shorter symptom duration.

8 Sep 2020

Hydroxychloroquine is not a possible defense against COVID-19, study shows

Researchers at Case Western Reserve University have added to the growing body of understanding about how hydroxychloroquine (HCQ) is not a possible defense against COVID-19.

17 Aug 2020

New method helps pinpoint new potential therapeutic targets for lupus

A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders.

8 Jul 2020

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

The ongoing COVID-19 pandemic has cost hundreds of thousands of human lives, besides more than 11 million cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease was initially thought to be more severe in the elderly and those with pre-existing medical conditions. However, it started to manifest in children after the peak of the first wave.

7 Jul 2020

Systemic Lupus Erythematosus News and Research

Steroids used to treat inflammatory disease increases risk of cardiovascular disease

Mymee's clinical trial demonstrates health-related quality of life improvements in lupus patients

Study: Hydroxychloroquine has no effect on abnormal heart rhythm in lupus patients with CKD

Black patients with lupus have higher risk of stroke and ischemic heart disease

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

Patients with rheumatic diseases reported antimalarial drug shortages during COVID-19

Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA or lupus patients

Pre-existing anti-IFN autoantibodies may worsen COVID-19 in lupus patients

Lung biomarkers may predict severe COVID-19

Exuberant activation of immune cells in severe COVID-19 resembles lupus

Auto-antibodies may explain why some people develop severe COVID-19

Targeted treatment for systemic lupus erythematosus

Memory B cells indicate durable immunity in COVID-19

Hydroxychloroquine is not a possible defense against COVID-19, study shows

New method helps pinpoint new potential therapeutic targets for lupus

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

Hydroxychloroquine suppresses 'trained immunity'

Researchers develop new method to measure hydroxychloroquine levels in SLE patients

Study examines changes in prescription patterns during COVID-19 pandemic

Gene variants can increase risk of schizophrenia, shows study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News